- Home
- CIGI vs GRFS Comparison
CIGI vs GRFS Comparison
Compare CIGI & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CIGI | GRFS |
|---|---|---|
| Founded | 1972 | 1940 |
| Country | Canada | Spain |
| Employees | N/A | 25247 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.5B |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | CIGI | GRFS |
|---|---|---|
| Price | $92.71 | $7.87 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 2 |
| Target Price | ★ $176.25 | $10.15 |
| AVG Volume (30 Days) | 305.5K | ★ 587.0K |
| Earning Date | 05-05-2026 | 07-28-2022 |
| Dividend Yield | 0.29% | ★ 1.80% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.28 | $4.49 |
| Revenue Next Year | $8.30 | $6.42 |
| P/E Ratio | $57.57 | ★ $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $90.93 | $7.39 |
| 52 Week High | $171.20 | $11.14 |
Technical Indicators
Market Signals| Indicator | CIGI | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 34.34 | 44.70 |
| Support Level | N/A | $7.52 |
| Resistance Level | $120.37 | $9.78 |
| Average True Range (ATR) | 4.26 | 0.22 |
| MACD | -1.00 | -0.04 |
| Stochastic Oscillator | 10.09 | 35.23 |
Price Performance
Historical ComparisonAbout CIGI Colliers International Group Inc. Subordinate Voting Shares
Colliers International Group Inc provides commercial real estate professional services and investment management to corporate and institutional clients across different countries around the world. Its operating segments are Commercial Real Estate, Engineering and Investment Management. Maximum revenue for the company is generated from its Commercial Real Estate segment, which offers services like transaction and debt finance services, outsourcing in property management, valuation and advisory, loan servicing, and others. Geographically, the company generates maximum revenue from the United States followed by Canada, Euro currency countries, Australia, the United Kingdom, Poland, China, India, and other regions.
About GRFS Grifols S.A.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.